Compare Charles River Laboratories Intl. Inc (CRL) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Marqeta Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $303.03 (market cap $14.23B), while Marqeta Inc trades at $18.04 (market cap $1.82B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 7.8× Marqeta Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Marqeta Inc for 44 Days on average.
| CRL | MQ | |
|---|---|---|
Market Cap | $14.23B | $1.82B |
Volume | 1,176,885 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $310.77 | $20.32 |
52-Week Low | $149.93 | $15.04 |
Typical Hold Time | 33 Days | 44 Days |
Enterprise Value | $17.06B | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Marqeta (MQ) trades at $17.86, up 4.69% with a bullish technical outlook. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow generation in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives. However, valuation remains elevated with a P/E of 193.83 and EV/EBITDA of 54.37 despite modest profitability metrics.
MQ presents a mixed investment case with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and product innovation, though faces risks from contract renewals and competitive pressure. Analyst consensus at $11.38 suggests caution despite recent positive earnings revisions and institutional interest in the fintech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
